Project Grant P01CA298991
Award Date 8/11/25
Completion Date 7/31/30
Dollars Obligated $2.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $509,246 to the Regents of the University of Michigan to conduct research on early drivers of prostate cancer lineage plasticity. The project aims to identify key transcriptional regulators that repress androgen receptor signaling and promote alternate differentiation programs in prostate cancer, with the goal of preventing lineage plasticity and disease progression. By...
- The U.S. National Cancer Institute (NCI) awarded a 5-year, $680,433 Project Grant to the University of California, San Francisco (UCSF) under the NCI's Cancer Detection and Diagnosis Research (CFDA 93.394) program. The grant supports research aimed at using cutting-edge spatial proteogenomic technologies and pathology artificial intelligence (PAI) to improve prognostic estimation and elucidate the underlying biology driving PAI outcomes in prostate cancer. The project seeks to: 1) understand the...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $603,981 to the University of Wisconsin-Madison to conduct research on integrated clinical-grade genomic and pathology artificial intelligence (AI) biomarkers for high-risk prostate cancer. The key objectives are to: 1) validate genomic and pathology AI as prognostic biomarkers for high-risk prostate cancer patients; 2) validate genomic and pathology AI as...
- This federal Project Grant award of $627,474.00 from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports a research project titled "Mapping the Epigenetic Dynamics of Prostate Cancer Progression: Integrating Liquid Biopsies and Single-Cell Epigenomics for Early Detection of Lineage Plasticity and Clinical Decision-Making." The project aims to utilize innovative epigenomic methods and signatures to better understand...
- The National Cancer Institute awarded a $571,271 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston. The goal of this 5-year research project is to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer, an aggressive form of the disease with limited treatment options. The project will explore using a small molecule drug conjugate that targets the prostate-specific membrane...
- This federal Project Grant award of $192,564 from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) supports Yale University's research to develop an innovative dual-target protein degrader that simultaneously inhibits lineage plasticity and therapy resistance drivers in metastatic castration-resistant prostate cancer (mCRPC). The research aims to overcome mCRPC's remarkable adaptability and lineage switching, which enable evasion of targeted therapies....
- The National Cancer Institute awarded a 5-year, $632,906 Project Grant to Tulane University under the Cancer Biology Research federal grant program (CFDA 93.396). The grant aims to elucidate a novel role for the androgen receptor (AR) in promoting prostate cancer progression and therapeutic resistance through its RNA-binding activity. Specifically, the research will investigate how AR binds to and regulates the expression of key splicing factors, leading to efficient splicing and expression of...
- The National Cancer Institute (NCI) awarded a $139,184 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Fred Hutchinson Cancer Center in Seattle, Washington. The grant period runs from July 1, 2025 to June 30, 2027. The primary objective of this project is to elucidate how prostate cancer utilizes the RNA components of the protein synthesis machinery, such as transfer RNA (tRNA) and 5' untranslated regions (UTRs), to support lineage plasticity and...
- The University of Pennsylvania received a $371,719 Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research program) to conduct research towards characterizing epigenetic targets in prostate cancer. The 5-year project, awarded on March 1, 2025, aims to identify, characterize, and therapeutically target co-factors and chromatin-associated proteins involved in the androgen receptor signaling pathway in prostate cancer. Specifically, the research will...
- This federal Project Grant award in the amount of $1,229,700.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is supporting research conducted by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts focused on "DISSECTION OF MOLECULAR ASSOCIATIONS OF RESPONSE TO NEOADJUVANT ANTIANDROGEN THERAPIES IN HIGH-RISK LOCALIZED PROSTATE CANCER." The 4-year research project aims to advance the...